

Date: 28.06.2021

To,  
**B S E Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001

**Sub: Annual Secretarial Compliance Report for the year ended 31<sup>st</sup> March 2021**

**Company Scrip Code: 532167**

Dear Sir/Ma'am,

Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read along with SEBI Circular no CIR/CFD/CMD 1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company issued by **M/s. Maulik Bhavsar & Associates, Practicing Company Secretaries** for the financial year 2020 -21.

This is for the information of the Exchange and the Members.

Thanking you,  
Yours faithfully,

Thanking you,  
Yours faithfully,  
For **Omkar Pharmachem Limited**



**Bhawani Shankar Goyal**  
(Managing Director)  
**DIN: 03255804**  
**Address:** H NO.77 Nangal Chaudhary Teh. Narnaul,  
Dist. Mahendergarh Nangal Chaudhary 123023 HR

Enc-a/a



**MAULIK BHAVSAR & ASSOCIATES**  
Company Secretaries

**Secretarial compliance report of OMKAR PHARMACHEM LIMITED**  
**for the year ended 31.03.2021**

To,  
**OMKAR PHARMACHEM LIMITED**  
501, MAHAKANT BUILDING OPP V.S.HOSPITAL,  
ASHRAM ROAD ELLISBRIDGE,  
AHMEDABAD GJ 380006 IN

We have conducted the Secretarial Compliance Audit of OMKAR PHARMACHEM LIMITED as per the applicable SEBI (Securities and Exchange Board of India) Regulations and the circulars/ guidelines issued thereunder for the Financial Year ended 31st March 2021. The audit was conducted in a manner that provided me with a reasonable basis for evaluating the statutory compliances and expressing my opinion thereto.

We, MAULIK BHAVSAR & ASSOCIATES, Practicing Company Secretary, Ahmedabad have examined:

- (a) all the documents and records made available to us and explanation provided by M/s. Omkar Pharmachem Limited ("the listed entity"),
- (b) the filings/ submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity, - <https://www.omkarpharmachem.co.in/>
- (d) any other document/ filing, as may be relevant, which has been relied upon to make this certification,

for the year ended **31<sup>st</sup> March, 2021** in respect of compliance with the provisions of :

- (a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- (b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 : **N.A. during the year under review**
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

12A, Manmohan Complex, B/h. Navrangpura Police Station, Navrangpura, Ahmedabad – 380009

Mo : 9428599185, Mail : [csmaulikbhavsar@gmail.com](mailto:csmaulikbhavsar@gmail.com)

Website : <http://www.csmaulikbhavsar.com/>



- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **N.A. during the year under review**
- (e) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; **N.A. during the year under review**
- (f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; **N.A. during the year under review**
- (g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2013; **N.A. during the year under review**
- (h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (i) SEBI (Depository and Participant) Regulation, 2018

and circulars/ guidelines issued thereunder; and based on the above examination, I/We hereby report that, during the Review Period:

- (a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder,
- (b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder insofar as it appears from my/our examination of those records.
- (c) As per the information provided by the Management of the company, there is no such action taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges.
- (d) The listed entity is not required to take any actions as there was no observations made in previous reports for the year ended 31<sup>st</sup> March, 2020:

**Note :** As per the information and related documents provided to us, We have verified the disclosures and compliances to be made by the Listed entity – **Omkar Pharmachem Limited** only during FY 2020-21.

Place : Ahmedabad  
Date : 22.06.2021

For Maulik Bhavsar & Associates  
Company Secretaries

MAULIK ANILKUMAR BHAVSAR  
Digitally signed by MAULIK ANILKUMAR BHAVSAR  
Date: 2021.06.22 19:56:18 +05'30'

Maulik Bhavsar (Proprietor)  
Mem. No. 11139, CP No. 11591

**UDIN F011139C000499000**